Endocytosis and cancer

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 12, 2013, Pages

  Mellman, Ira ^a   Yarden, Yosef ^b  

^a GENENTECH INC   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889053478     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a016949     Document Type: Article

References (177)

1. Abella JV, Peschard P, Naujokas MA, Lin T, Saucier C, Urbe S, Park M. 2005. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25: 9632-9645.
2. Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, Castellani L, Alema S, Alimandi M, Segatto O. 2003. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22: 4221-4234.
3. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, Pawson T, Muthuswamy SK. 2006. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 8: 1235-1245.
4. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. 2004. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268-5282.
5. Balaji K, Mooser C, Janson CM, Bliss JM, Hojjat H, Colicelli J. 2012. RIN1 orchestrates the activation of RAB5 GTPases and ABL tyrosine kinases to determine the fate of EGFR. J Cell Sci 125: 5887-5896.
6. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M, et al. 2003. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 63: 1731-1736.
7. Bao J, Gur G, Yarden Y. 2003. Src promotes destruction of cCbl: Implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci 100: 2438-2443.
8. Bar-Sagi D, Feramisco JR. 1986. Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science 233: 1061-1068.
9. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. 2012a. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 366: 520-529.
10. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. 2012b. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119.
11. Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA. 2012. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. Int J Cancer 133: 43-57.
12. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. 1996. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271: 5251-5257.
13. Ben-Kasus T, Schechter B, Sela M, Yarden Y. 2007. Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Mol Oncol 1: 42-54.
14. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. 2009. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci 106: 3294-3299.
15. Blagosklonny MV. 2000. p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 14: 1901-1907.
16. Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM. 2012. Targeting the hepatocyte growth factor-cMETaxis in cancer therapy. J Clin Oncol 30: 3287-3296.
17. Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, Lui MY, Colleoni GW, Antonescu CR, Ladanyi M, et al. 2001. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 159: 411-415.
18. Brodsky FM. 2012. Diversity of clathrin function: New tricks for an old protein. Annu Rev Cell Dev Biol 28: 309-336.
19. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B. 2012. Rab25 is overexpressed in Mullerian serous carcinoma compared to malignant mesothelioma. Virchows Arch 460: 193-202.
20. Cai JH, Zhao R, Zhu JW, Jin XL, Wan FJ, Liu K, Ji XP, Zhu YB, Zhu ZG. 2010. Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma. J Gastrointest Surg 14: 1248-1257.
21. Caswell PT, Spence HJ, Parsons M, White DP, Clark K, Cheng KW, Mills GB, Humphries MJ, Messent AJ, Anderson KI, et al. 2007. Rab25 associates with a5b1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 13: 496-510.
22. Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC. 2008. Rab-coupling protein coordinates recycling of a5b1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol 183: 143-155.
23. Caswell PT, Vadrevu S, Norman JC. 2009. Integrins: Masters and slaves of endocytic transport. Nat Rev Mol Cell Biol 10: 843-853.
24. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, et al. 2004. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256.
25. Christoforides C, Rainero E, Brown KK, Norman JC, Toker A. 2012. PKD controls avb3 integrin recycling and tumor cell invasive migration through its substrate Rabaptin-5. Dev Cell 23: 560-572.
26. Chua BT, Lim SJ, Tham SC, Poh WJ, Ullrich A. 2010. Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Mol Oncol 4: 323-334.
27. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. 2010. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 464: 783-787.
28. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y. 2002. Druginduced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy. EMBO J 21: 2407-2417.
29. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. 2004. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 5: 1165-1170.
30. Deborde S, Perret E, Gravotta D, Deora A, Salvarezza S, Schreiner R, Rodriguez-Boulan E. 2008. Clathrin is a key regulator of basolateral polarity. Nature 452: 719-723.
31. de la Vega M, Burrows JF, Johnston JA. 2011. Ubiquitination: Added complexity in Ras and Rho family GTPase function. Small GTPases 2: 192-201.
32. Di Guglielmo GM, Baass PC, Ou WJ, Posner BI, Bergeron JJ. 1994. Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. EMBO J 13: 4269-4277.
33. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM. 2000. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19: 1547-1555.
34. Dozynkiewicz MA, Jamieson NB, Macpherson I, Grindlay J, van den Berghe PV, von Thun A, Morton JP, Gourley C, Timpson P, Nixon C, et al. 2012. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell 22: 131-145.
35. Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR. 2012. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res 72: 4405-4416.
36. Eppinga RD, Krueger EW, Weller SG, Zhang L, Cao H, McNiven MA. 2012. Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. Oncogene 31: 1228-1241.
37. Ezratty EJ, Partridge MA, Gundersen GG. 2005. Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase. Nat Cell Biol 7: 581-590.
38. Fang P, Zhao Z, Tian H, Zhang X. 2012. RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma. Tumour Biol 33: 1511-1518.
39. Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M, et al. 2013. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci 110: 1815-1820.
40. Filosto S, Khan EM, Tognon E, Becker C, Ashfaq M, Ravid T, Goldkorn T. 2011. EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. PloS ONE 6: e23240.
41. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S. 2007. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci 104: 13092-13097.
42. French AR, Sudlow GP, Wiley HS, Lauffenburger DA. 1994. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. J Biol Chem 269: 15749-15755.
43. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. 2005. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc Natl Acad Sci 102: 1915-1920.
44. Frosi Y, Anastasi S, Ballaro C, Varsano G, Castellani L, Maspero E, Polo S, Alema S, Segatto O. 2010. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol 189: 557-571.
45. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, Sommer T, Birchmeier W. 2002. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 4: 222-231.
46. Gamou S, Shimizu N. 1995. Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett 357: 161-164.
47. Garrett WS, Chen LM, Kroschewski R, Ebersold M, Turley S, Trombetta S, Galan JE, Mellman I. 2000. Developmental control of endocytosis in dendritic cells by Cdc42. Cell 102: 325-334.
48. Ghiglione C, Carraway KL 3rd, Amundadottir LT, Boswell RE, Perrimon N, Duffy JB. 1999. The transmembrane molecule kekkon 1 acts in a feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis. Cell 96: 847-856.
49. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. 2008. Caveolin-1 in tumor progression: The good, the bad and the ugly. Cancer Metastasis Rev 27: 715-735.
50. Goh LK, Huang F, Kim W, Gygi S, Sorkin A. 2010. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J Cell Biol 189: 871-883.
51. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS. 2007. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28: 1408-1417.
52. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, et al. 2004. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281.
53. Haj FG, Verveer PJ, Squire A, Neel BG, Bastiaens PI. 2002. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295: 1708-1711.
54. Han W, Zhang T, Yu H, Foulke JG, Tang CK. 2006. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther 5: 1361-1368.
55. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
56. Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, et al. 2010. Epigenetic downregulation of human disabled homolog 2 switches TGF-b from a tumor suppressor to a tumor promoter. J Clin Invest 120: 2842-2857.
57. He H, Dai F, Yu L, She X, Zhao Y, Jiang J, Chen X, Zhao S. 2002. Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr 10: 231-242.
58. Hedman H, Henriksson R. 2007. LRIG inhibitors of growth factor signalling-Double-edged swords in human cancer? Eur J Cancer 43: 676-682.
59. Howe CL, Mobley WC. 2005. Long-distance retrograde neurotrophic signaling. Curr Opin Neurobiol 15: 40-48.
60. Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, Lin CY, Lee HJ, Wang YN, Liu M, Liao HW, et al. 2011. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nature Cell Biol 13: 174-181.
61. Huotari J, Helenius A. 2011. Endosome maturation. EMBO J 30: 3481-3500.
62. Hynes NE, MacDonald G. 2009. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
63. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S, McLendon R, Wesseling P. 2009. Robust detection of EGFR copy number changes and EGFR variant III: Technical aspects and relevance for glioma diagnostics. Brain Pathol 19: 661-671.
64. Jewell JL, Russell RC, Guan KL. 2013. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol 14: 133-139.
65. Joffre C, Barrow R, Menard L, Calleja V, Hart IR, Kermorgant S. 2011. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 13: 827-837.
66. Jura N, Bar-Sagi D. 2006. Mapping cellular routes of Ras: A ubiquitin trail. Cell Cycle 5: 2744-2747.
67. Kales SC, Ryan PE, Nau MM, Lipkowitz S. 2010. Cbl and human myeloid neoplasms: The Cbl oncogene comes of age. Cancer Res 70: 4789-4794.
68. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428.
69. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. 2007. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 13: 4400-4406.
70. Katzmann DJ, Babst M, Emr SD. 2001. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell 106: 145-155.
71. Khan EM, Lanir R, Danielson AR, Goldkorn T. 2007. Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking. FASEB J 22: 910-917.
72. Kobayashi S, Sawano A, Nojima Y, Shibuya M, Maru Y. 2004. The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1). FASEB J 18: 929-931.
73. Koefoed K, Steinaa L, Soderberg JN, Kjaer I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, et al. 2011. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 3: 584-595.
74. Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, et al. 2011. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERa-positive breast cancer. Mol Cancer Res 9: 1406-1417.
75. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL III, Sweeney C. 2004. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056.
76. Lander HM. 1997. An essential role for free radicals and derived species in signal transduction. FASEB J 11: 118-124.
77. Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149: 274-293.
78. Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA. 2003. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 278: 5292-5299.
79. Lee YY, Do IG, Park YA, Choi JJ, Song SY, Kim CJ, Kim MK, Song TJ, Park HS, Choi CH, et al. 2010. Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix. Cancer Biol Ther 10: 329-335.
80. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y. 1998. Differential endocytic routing of homoand hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17: 3385-3397.
81. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, et al. 2006. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6: 245.
82. Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y. 1996. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 12: 1117-1125.
83. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. 1998. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12: 3663-3674.
84. Li L, Cohen SN. 1996. Tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85: 319-329.
85. Li J, Ballif BA, Powelka AM, Dai J, Gygi SP, Hsu VW. 2005. Phosphorylation of ACAP1 by Akt regulates the stimulation-dependent recycling of integrin b1 to control cell migration. Dev Cell 9: 663-673.
86. Li J, Peters PJ, Bai M, Dai J, Bos E, Kirchhausen T, Kandror KV, Hsu VW. 2007. An ACAP1-containing clathrin coat complex for endocytic recycling. J Cell Biol 178: 453-464.
87. Lock JG, Stow JL. 2005. Rab11 in recycling endosomes regulates the sorting and basolateral transport of E-cadherin. Mol Biol Cell 16: 1744-1755.
88. Lu A, Tebar F, Alvarez-Moya B, Lopez-Alcala C, Calvo M, Enrich C, Agell N, Nakamura T, Matsuda M, Bachs O. 2009. A clathrin-dependent pathway leads to KRas signaling on late endosomes en route to lysosomes. J Cell Biol 184: 863-879.
89. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
90. Mak HH, Peschard P, Lin T, Naujokas MA, Zuo D, Park M. 2007. Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway. Oncogene 26: 7213-7221.
91. Mayor S, Parton RG, Donaldson JG. 2014. Clathrin-independent pathways of endocytosis. Cold Spring Harb Perspect Biol doi:10.1101/cshperspect.a016758.
92. Mellman I. 1996a. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 12: 575-625.
93. Mellman I. 1996b. Membranes and sorting. Curr Opin Cell Biol 8: 497-498.
94. Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H. 2011. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. PloS ONE 6: e25301.
95. Mills GB, Jurisica I, Yarden Y, Norman JC. 2009. Genomic amplicons target vesicle recycling in breast cancer. J Clin Invest 119: 2123-2127.
96. Morishige M, Hashimoto S, Ogawa E, Toda Y, Kotani H, Hirose M, Wei S, Hashimoto A, Yamada A, Yano H, et al. 2008. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat Cell Biol 10: 85-92.
97. Mosesson Y, Mills GB, Yarden Y. 2008. Derailed endocytosis: An emerging feature of cancer. Nat Rev Cancer 8: 835-850.
98. Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosseline P, et al. 2010. Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
99. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE, et al. 2012. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32: 1252-1265.
100. Muthuswamy SK, Gilman M, Brugge JS. 1999. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homoand heterodimers. Mol Cell Biol 19: 6845-6857.
101. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ. 1996. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-5086.
102. Nanes BA, Chiasson-MacKenzie C, Lowery AM, Ishiyama N, Faundez V, Ikura M, Vincent PA, Kowalczyk AP. 2012. p120-catenin binding masks an endocytic signal conserved in classical cadherins. J Cell Biol 199: 365-380.
103. Neckers L, Ivy SP. 2003. Heat shock protein 90. Curr Opin Oncol 15: 419-424.
104. Neckers L, Workman P. 2012. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 18: 64-76.
105. Normanno N, Bianco C, De Luca A, Salomon DS. 2001. The role of EGF-related peptides in tumor growth. Front Biosci 6: D685-D707.
106. Oren M, Rotter V. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: a001107.
107. Osmani N, Peglion F, Chavrier P, Etienne-Manneville S. 2010. Cdc42 localization and cell polarity depend on membrane traffic. J Cell Biol 191: 1261-1269.
108. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
109. Palacios F, Schweitzer JK, Boshans RL, D'Souza-Schorey C. 2002. ARF6-GTP recruits Nm23-H1 to facilitate dynamin-mediated endocytosis during adherens junctions disassembly. Nat Cell Biol 4: 929-936.
110. Palacios F, Tushir JS, Fujita Y, D'Souza-Schorey C. 2005. Lysosomal targeting of E-cadherin: A unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol 25: 389-402.
111. Palamidessi A, Frittoli E, Garre M, Faretta M, Mione M, Testa I, Diaspro A, Lanzetti L, Scita G, Di Fiore PP. 2008. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell 134: 135-147.
112. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101: 13306-13311.
113. Parachoniak CA, Park M. 2012. Dynamics of receptor trafficking in tumorigenicity. Trends Cell Biol 22: 231-240.
114. Parachoniak CA, Luo Y, Abella JV, Keen JH, Park M. 2011. GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell 20: 751-763.
115. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simoes-Correia J, Oliveira MJ, et al. 2012. Epithelial Eand P-cadherins: Role and clinical significance in cancer. Biochim Biophys Acta 1826: 297-311.
116. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, Zurrida S, Maisonneuve P, Viale G, Di Fiore PP. 2004. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 167: 215-221.
117. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. 2010. Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70: 588-597.
118. Pierini LM, Lawson MA, Eddy RJ, Hendey B, Maxfield FR. 2000. Oriented endocytic recycling of a5b1 in motile neutrophils. Blood 95: 2471-2480.
119. Pines G, Huang PH, Zwang Y, White FM, Yarden Y. 2010. EGFRvIV: A previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene 29: 5850-5860.
120. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, et al. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15: 2452-2467.
121. Piper RC, Dikic I, Lukacs G. 2014. Ubiquitin-dependent sorting in endocytosis. Cold Spring Harb Perspect Biol doi:10.1101/cshperspect.a016808.
122. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. 2011. RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer 11: 761-774.
123. Raiborg C, Stenmark H. 2009. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458: 445-452.
124. Ramsay AG, Keppler MD, Jazayeri M, Thomas GJ, Parsons M, Violette S, Weinreb P, Hart IR, Marshall JF. 2007. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin avb6. Cancer Res 67: 5275-5284.
125. Rao DS, Bradley SV, Kumar PD, Hyun TS, Saint-Dic D, Oravecz-Wilson K, Kleer CG, Ross TS. 2003. Altered receptor trafficking in Huntingtin Interacting Protein 1transformed cells. Cancer Cell 3: 471-482.
126. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA. 1990. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci 87: 1377-1380.
127. Riemann A, Schneider B, Ihling A, Nowak M, Sauvant C, Thews O, Gekle M. 2011. Acidic environment leads to ROS-induced MAPK signaling in cancer cells. PloS ONE 6: e22445.
128. Roberts M, Barry S, Woods A, van der Sluijs P, Norman J. 2001. PDGF-regulated rab4-dependent recycling of avb3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol 11: 1392-1402.
129. Rogaia D, Grignani F, Carbone R, Riganelli D, LoCoco F, Nakamura T, Croce CM, Di Fiore PP, Pelicci PG. 1997. The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner. Cancer Res 57: 799-802.
130. Roy S, Wyse B, Hancock JF. 2002. H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis. Mol Cell Biol 22: 5128-5140.
131. V600E positive papillary thyroid cancers. Surgery 144: 908-913; discussion 913-904.
132. Ruivenkamp CA, van Wezel T, Zanon C, Stassen AP, Vlcek C, Csikos T, Klous AM, Tripodis N, Perrakis A, Boerrigter L, et al. 2002. Ptprj is a candidate for the mouse coloncancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet 31: 295-300.
133. Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M, Thiessen C, Tickenbrock L, Schwable J, Brandts C, et al. 2007. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 110: 1004-1012.
134. Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, Haviv S, Asara JM, Pandolfi PP, Cantley LC. 2011. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Sig 4: ra13.
135. Scott RP, Eketjall S, Aineskog H, Ibanez CF. 2005. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem 280: 13442-13449.
136. Senda K, Goi T, Hirono Y, Katayama K, Yamaguchi A. 2007. Analysis of RIN1 gene expression in colorectal cancer. Oncol Rep 17: 1171-1175.
137. Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN, Edmondson RJ. 2009. Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 101: 498-503.
138. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. 2001. Regulation of receptor fate by ubiquitination of activated b2-adrenergic receptor and b-arrestin. Science 294: 1307-1313.
139. Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, et al. 2007. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 26: 6968-6978.
140. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP, Polo S. 2005. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci 102: 2760-2765.
141. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. 2008. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 15: 209-219.
142. So CW, Caldas C, Liu MM, Chen SJ, Huang QH, Gu LJ, Sham MH, Wiedemann LM, Chan LC. 1997. EEN encodes for a member of a new family of proteins containing an Src homology 3 domain and is the third gene located on chromosome 19p13 that fuses to MLL in human leukemia. Proc Natl Acad Sci 94: 2563-2568.
143. Sordella R, Bell DW, Haber DA, Settleman J. 2004. Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 305: 1163-1167.
144. Sorkin A, von Zastrow M. 2009. Endocytosis and signalling: Intertwining molecular networks. Nat Rev Mol Cell Biol 10: 609-622.
145. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. 2010. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci 107: 13252-13257.
146. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. 2002. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8: 1720-1730.
147. Sporn MB, Todaro GJ. 1980. Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878-880.
148. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, et al. 2012. HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2: 922-933.
149. Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF. 2001. Rasactivated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell 1: 73-82.
150. Tanemura A, Nagasawa T, Inui S, Itami S. 2005. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: Immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430.
151. Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel PS, Ng T, et al. 2009. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol 19: 1788-1798.
152. Teckchandani A, Toida N, Goodchild J, Henderson C, Watts J, Wollscheid B, Cooper JA. 2009. Quantitative proteomics identifies a Dab2/integrin module regulating cell migration. J Cell Biol 186: 99-111.
153. Teis D, Wunderlich W, Huber LA. 2002. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell 3: 803-814.
154. Thien CB, Langdon WY. 2001. Cbl: Many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2: 294-307.
155. Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
156. Tomshine JC, Severson SR, Wigle DA, Sun Z, Beleford DA, Shridhar V, Horazdovsky BF. 2009. Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1. J Biol Chem 284: 26331-26339.
157. Trebinska A, Rembiszewska A, Ciosek K, Ptaszynski K, Rowinski S, Kupryjanczyk J, Siedlecki JA, Grzybowska EA. 2010. HAX-1 overexpression, splicing and cellular localization in tumors. BMC Cancer 10: 76.
158. Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, et al. 1998. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J 17: 5948-5963.
159. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, Rong M, Li S, See LH, Nguyen KQ, et al. 2005. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci 102: 15901-15906.
160. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, et al. 2012. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783-1791.
161. Vieira AV, Lamaze C, Schmid SL. 1996. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274: 2086-2089.
162. Wang Y, Pennock S, Chen X, Wang Z. 2002. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 22: 7279-7290.
163. Wang Y, Du D, Fang L, Yang G, Zhang C, Zeng R, Ullrich A, Lottspeich F, Chen Z. 2006. Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling. EMBO J 25: 5058-5070.
164. Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, Furge KA, et al. 2009. Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 15: 319-324.
165. Wang Q, Gao Y, Tang Y, Ma L, Zhao M, Wang X. 2012. Prognostic significance of RIN1 gene expression in human non-small cell lung cancer. Acta Histochem 114: 463-468.
166. Wiley HS. 1988. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J Cell Biol 107: 801-810.
167. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. 1987. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci 84: 6899-6903.
168. Wong KK, Engelman JA, Cantley LC. 2010. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20: 87-90.
169. Woods AJ, White DP, Caswell PT, Norman JC. 2004. PKD1/ PKCm promotes avb3 integrin recycling and delivery to nascent focal adhesions. EMBO J 23: 2531-2543.
170. Worthylake R, Opresko LK, Wiley HS. 1999. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274: 8865-8874.
171. Xu L, Lubkov V, Taylor LJ, Bar-Sagi D. 2010. Feedback regulation of Ras signaling by Rabex-5-mediated ubiquitination. Curr Biol 20: 1372-1377.
172. Yin YX, Shen F, Pei H, Ding Y, Zhao H, Zhao M, Chen Q. 2012. Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis. Tumour Biol 33: 1581-1587.
173. Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, et al. 2010. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci 107: 6912-6917.
174. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. 2007. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450: 741-744.
175. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, et al. 2009. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest 119: 2171-2183.
176. {thorn}-ATPase. Science 334: 678-683.
177. Zwang Y, Yarden Y. 2009. Systems biology of growth factorinduced receptor endocytosis. Traffic 10: 349-363.